This article was originally published in The Tan Sheet
Diagnostic products developers Matritech and Inverness Medical Innovations have signed a manufacturing and distribution agreement to collaborate and seek FDA approval for OTC sale of the NMP22 BladderChek Test, the companies announce Nov. 6. The product, developed by Matritech, is the only FDA approved physician-office test for both the diagnosis and monitoring of bladder cancer, the companies say. The firms will assess market opportunity under their agreement and "anticipate the OTC distribution would be introduced in the U.S. as soon as FDA approval is received." Home diagnostic products already marketed by Inverness include the Clearblue and Fact Plus home pregnancy tests...
You may also be interested in...
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
The IGBA has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating healthcare professionals.